We are live on ! Find out more
BG

Bahl & Gaynor Portfolio holdings

AUM $19.8B
1-Year Est. Return 19.53%
This Fund
S&P 500
This Quarter Est. Return
+7.49%
1 Year Est. Return
+19.53%
3 Year Est. Return
+63.97%
5 Year Est. Return
+84.2%
10 Year Est. Return
+296.44%
AUM
$9.72B
AUM Growth
+$589M
Cap. Flow
-$37.2M
Cap. Flow %
-0.38%
Top 10 Hldgs %
31.39%
Holding
419
New
23
Increased
181
Reduced
152
Closed
9

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$48.3M
2
ABBV icon
AbbVie
ABBV
+$40.8M
3
SRE icon
Sempra
SRE
+$23.4M
4
CVX icon
Chevron
CVX
+$21.9M
5
HPQ icon
HP
HPQ
+$21.2M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$72M
2
ENB icon
Enbridge
ENB
+$61.3M
3
MSFT icon
Microsoft
MSFT
+$45.4M
4
KMB icon
Kimberly-Clark
KMB
+$42.1M
5
VIRT icon
Virtu Financial
VIRT
+$10.4M

Sector Composition

Rank Sector Weight
1 Technology 17.92%
2 Healthcare 16.37%
3 Financials 13.94%
4 Industrials 11.5%
5 Consumer Staples 11.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCR
401
DELISTED
CR Bard Inc.
BCR
– –
-2,267
Closed -$727K
13 14 15 16
17

Similar funds

NIM
NEOS Investment Management Westport, Connecticut $19.8B AUM 31.12% 1-Year Est. Return
HHII
H&H International Investment Palo Alto, California $20B AUM 9.66% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $20.1B AUM 30.42% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
P
&Partners Nashville, Tennessee $20.2B AUM 19.79% 1-Year Est. Return

Bahl & Gaynor's Q4 2017 Portfolio in Review

As of Q4 2017, Bahl & Gaynor held 419 positions worth $9.72B, up 6.4% from $9.13B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Bahl & Gaynor's Q4 2017 filing shows 23 new, 181 increased, 152 reduced and 9 closed positions. Its largest new stake was iShares Core High Dividend ETF: 534,010 shares worth $9.63M. The largest sale was Merck, an estimated $72M.

By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 17% a quarter earlier, followed by Healthcare and Financials.

  • Bahl & Gaynor's largest Q4 2017 buy was iShares Core High Dividend ETF: 534,010 shares worth $9.63M.
  • Bahl & Gaynor added most to Amgen in Q4 2017, an estimated $48.3M increase.
  • Bahl & Gaynor's biggest Q4 2017 reduction was Merck, cutting an estimated $72M.
  • Bahl & Gaynor fully exited Virtu Financial in Q4 2017, selling an estimated $10.4M.
  • Bahl & Gaynor's ten largest holdings make up 31% of its $9.72B portfolio in Q4 2017.
  • Bahl & Gaynor opened 23 new positions and closed 9 in Q4 2017.
  • Bahl & Gaynor's portfolio value rose 6.4% quarter-over-quarter to $9.72B.

Based on Bahl & Gaynor's 13F filing for Q4 2017, filed 13 Feb 2018.